FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,189,638 | -24.1% | 1,090,260 | -9.1% | 0.01% | -33.3% |
| Q1 2023 | $6,835,674 | +56244.2% | 1,199,241 | -0.3% | 0.01% | -50.0% |
| Q4 2022 | $12,132 | -100.0% | 1,202,355 | -44.1% | 0.02% | -74.6% |
| Q3 2022 | $48,188,000 | -7.5% | 2,150,276 | +2.3% | 0.07% | -1.4% |
| Q2 2022 | $52,092,000 | -1.1% | 2,102,161 | +54.7% | 0.07% | +20.0% |
| Q1 2022 | $52,674,000 | -36.2% | 1,358,636 | -3.7% | 0.06% | -26.8% |
| Q4 2021 | $82,578,000 | +45.9% | 1,411,341 | +47.8% | 0.08% | +32.3% |
| Q3 2021 | $56,611,000 | – | 955,137 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 716,392 | $11,126,000 | 12.18% |
| Polaris Venture Management Co. V, L.L.C. | 1,139,783 | $17,701,000 | 10.06% |
| Grosvenor Holdings, L.L.C. | 2,285,714 | $35,497,000 | 6.41% |
| Redmile Group, LLC | 11,216,809 | $174,197,000 | 5.83% |
| Casdin Capital, LLC | 2,550,000 | $39,601,500,000 | 4.10% |
| DAFNA Capital Management LLC | 470,000 | $7,299,000 | 2.74% |
| Ghost Tree Capital, LLC | 350,000 | $5,436,000 | 1.38% |
| Artal Group S.A. | 2,000,000 | $31,060,000 | 1.24% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,952,897 | $30,328,000 | 1.24% |
| Copernicus Capital Management, LLC | 75,000 | $1,165,000 | 1.08% |